The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
HOME > REGULATORY
REGULATORY
- Mandatory Generic Drug Use Still Impractical Due to People’s Lingering Distrust: MHLW
July 2, 2012
- MHLW Calls for Caution to Secondary Damage from Fainting After HPV Vaccination
June 29, 2012
- MHLW Proposes 2-Stage Discussions on Cost-Effective Assessment of Medical Technologies
June 29, 2012
- JPO Rules Actonel Patent Invalid; Ajinomoto Considering Appeal
June 29, 2012
- MHLW Talks to Drug Makers with Facilities Eligible for Exemption from Planned Power Outages
June 27, 2012
- Targets for Generic Drug Use Should Be Included in Medical Expenditure Optimization Plan: Mr Konishi of DPJ
June 26, 2012
- MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
June 26, 2012
- MHLW Approves 11 Products Including Additional Indication for Lyrica
June 26, 2012
- Median Review Time Down by About Half Since FY2007: PMDA
June 25, 2012
- Antipyretic/Analgesics Are Most Common Cause for Relief Benefits for Damage from ADRs: PMDA
June 25, 2012
- PMDA Adopts New Rule for Staff Re-Employment Effective This Month, No Uses Made Yet
June 25, 2012
- 166 Applications Received for Preliminary Interviews for Regulatory Strategy Consultation in First 9 Months: PMDA
June 25, 2012
- Claims of “Ineffective” Generics Might Be Due to Placebo Effect in Some Cases: Mr Yoshida of HIB
June 25, 2012
- MHLW to Strengthen Focus on Dementia with Budget Request for FY2013
June 22, 2012
- MHLW to Draft New Guidelines on Pharmacotherapy for Dementia
June 22, 2012
- Nichi-Iko No. 1 in Terms of the Number of Generics Listed in June; Pfizer at 4th
June 22, 2012
- 60% Rule Applied for 3 APIs in June’s Generic Listing
June 22, 2012
- Access System for Unapproved Drugs to Be Submitted at Next Ordinary Diet Session “at the Latest”: Mr Kawai of DPJ
June 21, 2012
- MHLW Calls for OTC Switch for Hyaluronate Sodium
June 21, 2012
- Establishment of Third-Party Organization “Historical”: DPJ Member Kawai
June 20, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…